Skip to main content
SpringerLink
Log in

Neue Formen der Insulinapplikation

Inhalatives Insulin, orales Insulin

Alternative routes of insulin administration

Inhalational insulin, oral insulin

  • Leitthema
  • Published:
Der Diabetologe Aims and scope

Zusammenfassung

Das erste inhalative Insulin wurde durch die zuständigen US-amerikanischen und europäischen Behörden im Januar 2006 zugelassen, womit dem Thema der alternativen Insulinapplikation in der diabetologischen Praxis zunehmend Bedeutung zukommt. Der vorliegende Beitrag erläutert die unterschiedlichen methodisch-technologischen Strategien, die bei der Entwicklung von inhalativem Insulin verfolgt werden, und gibt einen Überblick über die verfügbare klinische Literatur. Daneben wird auf künftige Entwicklungen im Bereich der oralen Insuline eingegangen.

Abstract

The first inhalational insulin was approved by American and European authorities in January 2006. Thus, the topic of alternative insulin application is of rising importance for diabetic patients and diabetes specialists. This review provides information on the different technological strategies of inhalational insulin development and gives an overview of the available clinical publications. In addition, the current knowledge on oral insulin formulations is presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8

Literatur

  1. Arbit E, Nosek L, Kapitza C et al. (2004) Oral insulin as first-line therapy in type 2 diabetes: a randomized-controlled pilot study. Diabetologia [Suppl 1] 47: A5

  2. Cefalu WT, Skyler JS, Kourides IA et al. (2001) Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 134: 203–207

    PubMed  Google Scholar 

  3. Clement S, Still GJ, Kosutic G (2002) The effects of timing of a standardized meal on absorption of a single oral dose of hexyl-insulin monoconjugate (HIM2) in patients with type 1 diabetes. Diabetes [Suppl 2] 51: A49

  4. Cook MN, Girman CJ, Stein PP et al. (2005) Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28: 995–1000

    PubMed  Google Scholar 

  5. DeFronzo RA, Bergenstal RM, Cefalu WT et al. (2005) Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 28: 1922–1928

    PubMed  Google Scholar 

  6. Fineberg SE, Kawabata T, Finco-Kent D et al. (2005) Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. J Clin Endocrinol Metab 90: 3287–3294

    Article  PubMed  Google Scholar 

  7. Freemantle N, Blonde L, Duhot D et al. (2005) Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 28: 427–428

    PubMed  Google Scholar 

  8. Gale EA (2001) Two cheers for inhaled insulin. Lancet 357: 324–325

    Article  PubMed  Google Scholar 

  9. Gelfand RA, Schwartz SL, Horton ML et al. (1998) Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus. Diabetes [Suppl 1] 47: A99

  10. Heinemann L, Heise T (2004) Current status of the development of inhaled insulin. Br J Diabetes Vasc Dis 4: 295–301

    Google Scholar 

  11. Heinemann L, Traut T, Heise T (1997) Time-action profile of inhaled insulin. Diabet Med 14: 63–72

    Article  PubMed  Google Scholar 

  12. Heinemann L, Klappoth W, Rave K et al. (2000) Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 23: 1343–1347

    PubMed  Google Scholar 

  13. Heise T, Heinemann L (2001) Rapid and long-acting insulin analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharmaceut Design 7: 1303–1325

    Article  Google Scholar 

  14. Heise T, Bott S, Tusek C et al. (2005) The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care 28: 2161–2169

    PubMed  Google Scholar 

  15. Henry RR, Mudaliar SR, Howland WC et al. (2003) Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care 26: 764–769

    PubMed  Google Scholar 

  16. Hermansen K, Ronnemaa T, Petersen AH et al. (2004) Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 27: 162–167

    PubMed  Google Scholar 

  17. Himmelmann A, Jendle J, Mellen A et al. (2003) The impact of smoking on inhaled insulin. Diabetes Care 26: 677–682

    PubMed  Google Scholar 

  18. Hollander PA, Blonde L, Rowe R et al. (2004) Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27: 2356–2362

    PubMed  Google Scholar 

  19. Hunt LM, Valenzuela MA, Pugh JA (1997) NIDDM patients‘ fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 20: 292–298

    PubMed  Google Scholar 

  20. Jendle JH, Karlberg BE (1996) Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scan J Clin Lab Invest 56: 555–561

    Google Scholar 

  21. Kapitza C, Arbit E, Abbas R et al. (2003) Oral insulin: proof of concept in type 2 diabetic patients. Diabetes [Suppl 1] 52: A37

  22. Kapitza C, Hompesch M, Scharling B et al. (2004) Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 6: 466–472

    Article  PubMed  Google Scholar 

  23. Kipnes M, Dandona P, Tripathy D et al. (2003) Control of postprandial glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 26: 421–426

    PubMed  Google Scholar 

  24. Koro CE, Bowlin SJ, Bourgeois N et al. (2004) Glycemic control 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 27: 17–20

    PubMed  Google Scholar 

  25. Lee DM (1992) Wie schmerzhaft ist die intensive Insulintherapie? Z Gesamt Inn Med 47: 266–269

    Google Scholar 

  26. Mather LE, Clauson P, Uy C et al. (2002) Pharmacokinetics and pharmacodynamics of pulmonary insulin using the AERx insulin diabetes management system during and after an upper respiratory tract infection. An open labelled crossover study in healthy subjects. Diabetologia [Suppl 2] 45: A261

  27. Patton JS, Bukar J, Nagarajan S (1999) Inhaled insulin. Adv Drug Deliv Rev 35: 235–247

    Article  PubMed  Google Scholar 

  28. Perera AD, Kapitza C, Nosek L et al. (2002) Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 25: 2276–2281

    PubMed  Google Scholar 

  29. Pfützner A, Heise T, Steiner S et al. (2000) Inhaled technosphere/insulin shows a low variability in metabolic action in type 2 diabetic patients. Diabetes [Suppl 1] 49: A121

  30. Rave K, Bott S, Heinemann L et al. (2005) Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28: 1077–1082

    PubMed  Google Scholar 

  31. Rosenstock J, Cappelleri JC, Bolinder B et al. (2004) Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 27: 1318–1323

    PubMed  Google Scholar 

  32. Saudek CD (1993) Future developments in insulin delivery systems. Diabetes Care [Suppl 3] 16: 122–132

    Google Scholar 

  33. Skyler JS, Cefalu WT, Kourides IA et al. (2001) Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357: 331–335

    Article  PubMed  Google Scholar 

  34. Skyler JS, Weinstock RS, Raskin P et al. (2005) Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 28: 1630–1635

    PubMed  Google Scholar 

  35. Wall DA (1995) Pulmonary absorption of peptides and proteins. Drug Delivery 2: 1–20

    Google Scholar 

  36. Weiss SR, Cheng SL, Kourides IA et al. (2003) Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 163: 2277–2282

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Profil Institut für Stoffwechselforschung GmbH, Hellersbergstraße 9, 41460 , Neuss

    S. Arnolds & T. Heise

Authors
  1. S. Arnolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Heise
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Arnolds.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arnolds, S., Heise, T. Neue Formen der Insulinapplikation. Diabetologe 2, 332–339 (2006). https://doi.org/10.1007/s11428-006-0062-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-006-0062-6

Schlüsselwörter

Keywords

Search

Navigation